Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the ...

Soleno Therapeutics Inc (SLNO) reports a strong initial market response to Vykat XR despite a significant net loss and high operational expenses in Q1 2025.

Investing.com -- Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares gained 2.6% after the biopharmaceutical company provided an update on the U.S. launch of its newly approved drug VYKAT XR and reported ...

Soleno has established a comprehensive support program, Soleno ONE™, to assist patients, caregivers and healthcare providers ...

Prescriptions of VYKAT XR have now been delivered to the first individuals living with PWS who have been prescribed the medication. “We are extremely pleased to begin delivering VYKAT XR ...